Teva VP Ika Abravanel resigns
The company plans to raise $20 million on the TASE at a company value of $200 million.
Drug development start-up Aposense Ltd. today filed a prospectus to raise $20 million in an IPO on the Tel Aviv Stock Exchange (TASE) at a company value of $200 million. Aposense seeks to apply apoptosis (programmed cell death) to develop personalized oncology, cardiology, and neurology treatments.
The company's first product is a molecular imaging product for brain cancer, which is undergoing a Phase II clinical trial. The company hopes to bring the drug to market by 2012.
Aposense hopes to receive $9 million from Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA), under the second stage of the companies' cooperation agreement. Teva invested $2 million in the first stage of their joint development of new cancer treatments
Aposense will later decide whether to continue its collaboration with Teva, and to equally share in expenses and commercial rights; to pay 25% of costs and reap 32% of revenue; or not to share in costs and receive 7% of royalties on sales.
In late 2009, Aposense signed a joint development and marketing agreement with Belgium's Ion Beam Applications SA (Euronext: IBAB). Aposense received a $2.5 million down payment when it signed the deal.
Aposense lost NIS 28.6 million in 2009. The company's revenue rose to NIS 645,000 in 2009 from NIS 7,000 in 2008, and NIS 83,000 in 2007.
Former Teva chairman Eli Hurvitz currently owns 1.92%, fully diluted, of Aposense. Hurvitz serves as chairman of Aposense. The stake of Pontifax Fund LP, which he founded, owns 7.1%. The company's largest shareholders is Bargal R&D Investments Ltd. with 18.1%, and other shareholders include Heartwood Ltd. with 10.4%, Ziegler-Meditech Equity Partners LP, Aposense co-founder vice chairman and CSO Dr. Ilan Ziv, with 13.8%, and CEO Yoram Ashery with 2.5%.
Published by Globes [online], Israel business news - www.globes-online.com - on May 16, 2010
© Copyright of Globes Publisher Itonut (1983) Ltd. 2010
You comment was recieved and soon will be published.
Load more comments
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.